(1)
BEDMINSTER, N.J., Feb. 25, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with Boston Children s Hospital (https://wistar.org/) to evaluate peptidyl arginine deiminase 4 (PAD4) inhibitors under development by Jubilant Therapeutics to explore the modulation of neutrophil extracellular traps (NETosis) in preclinical models of neutrophil regulation and rheumatoid arthritis (RA).
PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been implicated in the formation of NETs which is believed to contribute to pro-inflammation and disease progression in many autoimmune disorders including RA, fibrosis, lupus and ARDS.
Remdesivir Market 15
Remdesivir Market –Industry Trends and Forecast to 2028” focuses on the major drivers and restraints for the key players. These research report also provides Comprehensive analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Report is a professional and in-depth study on the current state of Industry. With 350 pages, 60 Figures And 220 Tables in it
Remdesivir Market report provides key statistics on the market status of the industry manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the
Remdesivir Market industry. Research market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. top key players and new comers in industry, competitive landscape, sales, price, revenue, gross margin, market share, market risks, opportunities, market barriers, and challenges.key statisti
), Application (Ebola, SARS-COV, MERS-COV, COVID-19
), End User (Hospitals, Clinics, Pharmacy and Drug Stores, Online Pharmacies), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Remdesivir market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 9,925.61 million by 2028 and will grow at a CAGR of 27.46% in the above mentioned forecast period.
a2zFebruary 16, 2021 18
Genetic Toxicology Testing Market report focused on the comprehensive analysis of current and future prospects of the Genetic Toxicology Testing industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Genetic Toxicology Testing market has been done in order to calculate the growth rates for each segment and sub-segments.
The global size is expected to Expand at Significant CAGR of +10% during forecast period (2021-2027).
Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs
News provided by
Share this article
Share this article
NEW HAVEN, Conn. and BENGALURU, India, Feb. 9, 2021 /PRNewswire/ Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
Under the scope of this partnership, Jubilant Biosys will provide research services to investigators at Yale University working on novel therapeutic targets. Areas of collaboration include medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology among others.
Yale Logo
Commenting on this collaboration, Marcel Velterop, President Jubilant Biosys said
Yale is one of the top-ranked academic institutions in the US and we at Jubilant Biosys are delighted to be able to support scientific endeavours of Investigators at Yale to pursue novel target ideas for unmet medical conditions. With our New Discove